Clinical Trial
2022-000565-40 Recruiting, Active
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
Disease
Disease type
Other
Orphan drug recognition
Yes
Patient type
Adult
Children
Funding
private
Members involved
Others investigators
Dr Marta Morales Ballús
Representative
Spain
Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8)
ERN EYE member investigating site
HCP : Principal investigators
Hospital Sant Joan de Déu, Spain
Adress
Passeig de Sant Joan de Déu, 2
8950 Esplugues de Llobregat, Barcelona
Spain